S2Medical AB (S2M) - Cash Flow Conversion Efficiency
Based on the latest financial reports, S2Medical AB (S2M) has a cash flow conversion efficiency ratio of -0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-306.89K ≈ $-33.03K USD) by net assets (Skr9.87 Million ≈ $1.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see S2Medical AB (S2M) market capitalisation for the company's overall valuation and market capitalisation.
S2Medical AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how S2Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
S2Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of S2Medical AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of S2Medical AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Faron Pharmaceuticals Oy
LSE:FARN
|
0.000x |
|
Watkin Jones PLC
LSE:WJG
|
-0.050x |
|
Churchill China plc
LSE:CHH
|
0.013x |
|
IMMERSION G. S.A. ZY 10
F:73W
|
3.367x |
|
Craven House Capital PLC
LSE:CRV
|
0.000x |
|
Alkemy Capital Investments Plc
LSE:ALK
|
1.013x |
|
STMicroelectronics NV
LSE:0INB
|
0.221x |
|
Aequus Pharmaceuticals Inc
V:AQS
|
0.003x |
Annual Cash Flow Conversion Efficiency for S2Medical AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of S2Medical AB from 2016 to 2025. View S2M share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.87 Million ≈ $1.06 Million |
Skr675.00K ≈ $72.64K |
0.068x | -83.96% |
| 2024-12-31 | Skr11.80 Million ≈ $1.27 Million |
Skr5.03 Million ≈ $541.40K |
0.426x | +104.28% |
| 2023-12-31 | Skr1.66 Million ≈ $178.42K |
Skr-16.52 Million ≈ $-1.78 Million |
-9.964x | -150.39% |
| 2022-12-31 | Skr7.07 Million ≈ $760.76K |
Skr-28.13 Million ≈ $-3.03 Million |
-3.979x | -197.08% |
| 2021-12-31 | Skr14.68 Million ≈ $1.58 Million |
Skr-19.67 Million ≈ $-2.12 Million |
-1.339x | -244.25% |
| 2020-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.389x | +42.87% |
| 2019-12-31 | Skr25.11 Million ≈ $2.70 Million |
Skr-17.10 Million ≈ $-1.84 Million |
-0.681x | -132.57% |
| 2018-12-31 | Skr43.55 Million ≈ $4.69 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.293x | +63.05% |
| 2017-12-31 | Skr7.38 Million ≈ $793.67K |
Skr-5.85 Million ≈ $-629.12K |
-0.793x | +28.05% |
| 2016-12-31 | Skr2.75 Million ≈ $296.05K |
Skr-3.03 Million ≈ $-326.18K |
-1.102x | -- |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more